Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge — Competitive Intelligence Brief

Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge (Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nicotine replacement therapy (NRT). Area: Hematology.

marketed Nicotine replacement therapy (NRT) Nicotinic acetylcholine receptors Hematology Small molecule

Target snapshot

Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge (Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge) — University of Wisconsin, Madison.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge TARGET	Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge	University of Wisconsin, Madison	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Placebo Tablet and Nicotine Patch	Placebo Tablet and Nicotine Patch	The Scripps Research Institute	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
bupropion + lozenge	bupropion + lozenge	University of Wisconsin, Madison	marketed	Antidepressant + nicotine replacement therapy	Norepinephrine transporter, dopamine transporter; nicotinic acetylcholine receptors
Mailed nicotine replacement therapy	Mailed nicotine replacement therapy	Massachusetts General Hospital	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
Nicotine Patch and Nicotine Lozenge	Nicotine Patch and Nicotine Lozenge	University of Wisconsin, Madison	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Transdermal nicotine patch	Transdermal nicotine patch	University of Pennsylvania	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Nicotine Mini-Lozenge for 11 Months	Nicotine Mini-Lozenge for 11 Months	University of Wisconsin, Madison	marketed	Nicotinic acetylcholine receptor agonist; Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nicotine replacement therapy (NRT) class)

1. University of Wisconsin, Madison · 4 drugs in this class
2. Ottawa Heart Institute Research Corporation · 1 drug in this class
3. The Scripps Research Institute · 1 drug in this class
4. US Department of Veterans Affairs · 1 drug in this class
5. Chrono Therapeutics, Inc. · 1 drug in this class
6. University of Chicago · 1 drug in this class
7. University of Maryland, Baltimore · 1 drug in this class
8. University of Miami · 1 drug in this class
9. University of California, San Francisco · 1 drug in this class